All In Biotech

Drug Trial Radar · NCT06205121

Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis

A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of a 12-week Administration of OATD-01, an Oral Inhibitor of Chitinase-1 (CHIT1), for the Treatment of Active Pulmonary Sarcoidosis (the KITE Study)

Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

96

Planned (sponsor's estimate)

Start

Mar 21, 2024

Primary completion

Aug 2027

Study completion Sep 2027

Sponsor

Lead sponsor
Molecure S.A.Industry
Sponsor type
Industry
First posted
Jan 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, randomized, double-blind, placebo-controlled, adaptive, multicenter study to evaluate the efficacy, safety, tolerability, Pharmacodynamics (PD), and Pharmacokinetics (PK) of OATD-01 in the treatment of subjects with active pulmonary sarcoidosis.

Conditions

  • Pulmonary Sarcoidosis

Interventions

  • OATD-01Drug

    OATD-01 is an oral inhibitor of chitinase-1 (CHIT1)

  • PlaceboDrug

    Matching placebo tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Response to treatmentTime frame: After 12 weeks of treatment, i.e. from baseline (randomization) visit to End-of-Treatment (EOT) visit.

Locations

28 sites in 8 countries. Site status is shown where the registry gives one.

  • Molecure Investigative Site

    Birmingham, Alabama · Withdrawn

  • Molecure Investigative Site

    Kansas City, Kansas · Withdrawn

  • Molecure Investigative Site

    Baltimore, Maryland · Recruiting

  • Molecure Investigative Site

    Rochester, Minnesota · Withdrawn

  • Molecure Investigative Site

    Cleveland, Ohio · Recruiting

  • Molecure Investigative Site

    Philadelphia, Pennsylvania · Recruiting

  • Molecure Investigative Site

    Charleston, South Carolina · Recruiting

  • Molecure Investigative Site

    Vejle, Denmark · Withdrawn

  • Molecure Investigative Site

    Bobigny, France · Withdrawn

  • Molecure Investigative Site

    Montpellier, France · Recruiting

  • Molecure Investigative Site

    Paris, France · Recruiting

  • Molecure Investigative Site

    Paris, France · Recruiting

  • Molecure Investigative Site

    Essen, Germany · Recruiting

  • Molecure Investigative Site

    Freiburg im Breisgau, Germany · Recruiting

  • Molecure Investigative Site

    Mainz-GE, Germany · Recruiting

  • Molecure Investigative Site

    Corfu, Greece · Withdrawn

  • Molecure Investigative Site

    Heraklion, Greece · Recruiting

  • Molecure Investigative Site

    Pátrai, Greece · Recruiting

  • Molecure Investigative Site

    Thessaloniki, Greece · Recruiting

  • Molecure Investigative Site

    Nieuwegein, Netherlands · Recruiting

  • Molecure Investigative Site

    Rotterdam, Netherlands · Recruiting

  • Molecure Investigative Site

    Bergen, Norway · Recruiting

  • Molecure Investigative Site

    Oslo, Norway · Recruiting

  • Molecure Investigative Site

    Birmingham, United Kingdom · Recruiting

  • Molecure Investigative Site

    Cambridge, United Kingdom · Withdrawn

  • Molecure Investigative Site

    Edinburgh, United Kingdom · Recruiting

  • Molecure Investigative Site

    London, United Kingdom · Recruiting

  • Molecure Investigative Site

    London, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.